PMID- 15227054
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20050202
LR  - 20181113
IS  - 0730-2347 (Print)
IS  - 0730-2347 (Linking)
VI  - 11
IP  - 3
DP  - 1984 Sep
TI  - Cardiac transplantation: current results at the Texas heart institute.
PG  - 228-32
AB  - The first series of cardiac transplants at the Texas Heart Institute began in May 
      of 1968 but was discontinued because of the complications of infection and 
      rejection. A second series of cardiac transplants was initiated in July of 1982 
      after the introduction of the immunosuppressant drug, cyclosporine. By August of 
      1984, 30 patients had undergone orthotopic cardiac transplantation for end-stage 
      cardiac disease. Of the patients in this series, four have died of rejection, two 
      of infectious complications, and one of an unknown cause. The remainder have all 
      returned to Class I New York Heart Association (NYHA) cardiac status. All 
      patients were reviewed in detail for suitability of cardiac transplantation and 
      presented to a cardiac transplant review board. All transplanted patients were 
      functional Class IV. Donor hearts were obtained locally or by long-distance 
      procurement. Ten of the hearts were obtained from an average distance of 250 
      miles from Houston. Donors ranged in age from 16 to 37 years. Requirements were 
      normal cardiac function with minimal use of inotropic support, no history of 
      cardiac disease, absence of cardiac arrest and absence of active infection. 
      Although only one of the patients in the initial group of transplants survived 1 
      year, to date there have been 11 survivors for more than 1 year in the current 
      series. Advances in cardiac transplantation have resulted in an improved 
      prognosis for the terminal cardiomyopathic patients requiring transplantation. 
      The use of cyclosporine, an immunosuppressant that spares the nonspecific immune 
      system, has been helpful in allowing patients to survive infections. The use of 
      the drug must be carefully monitored, however, because of its numerous 
      toxicities.
FAU - Okereke, O U
AU  - Okereke OU
AD  - Transplantation Unit, Division of Surgery, and the Cullen Cardiovascular Surgical 
      Research Laboratories, Texas Heart Institute of St. Luke's Episcopal and Texas 
      Children's Hospitals, Houston, Texas 77030, USA.
FAU - Frazier, O H
AU  - Frazier OH
FAU - Cooley, D A
AU  - Cooley DA
FAU - Waldenberger, F
AU  - Waldenberger F
FAU - Radovancevic, B
AU  - Radovancevic B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
PMC - PMC341717
EDAT- 1984/09/01 00:00
MHDA- 2004/07/01 05:00
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 2004/07/01 05:00 [medline]
PHST- 1984/09/01 00:00 [entrez]
PST - ppublish
SO  - Tex Heart Inst J. 1984 Sep;11(3):228-32.